scholarly journals CNS disease in younger patients with aggressive B-cell lymphoma: an analysis of patients treated on the Mabthera International Trial and trials of the German High-Grade Non-Hodgkin Lymphoma Study Group

2012 ◽  
Vol 23 (5) ◽  
pp. 1267-1273 ◽  
Author(s):  
N. Schmitz ◽  
S. Zeynalova ◽  
B. Glass ◽  
U. Kaiser ◽  
E. Cavallin-Stahl ◽  
...  
Keyword(s):  
B Cell ◽  
Hodgkin Lymphoma ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Study Group ◽  
High Grade ◽  
Younger Patients ◽  
Non Hodgkin Lymphoma ◽  
Lymphoma Study Group ◽  
Aggressive B Cell Lymphoma

Diffuse Large B-cell Lymphoma Arising in Nodular Lymphocyte Predominant Hodgkin Lymphoma. A Report of 21 Cases from the Nebraska Lymphoma Study Group

2003 ◽  
Vol 44 (11) ◽  
pp. 1903-1910 ◽  
Author(s):  
James Z. Huang ◽  
Dennis D. Weisenburger ◽  
Julie M. Vose ◽  
Timothy C. Greiner ◽  
Patricia Aoun ◽  
...  
Keyword(s):  
B Cell ◽  
Hodgkin Lymphoma ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Study Group ◽  
Large B Cell Lymphoma ◽  
Lymphoma Study Group ◽  
Large B Cell

Rituximab in Relapsed Lymphocyte Predominant Hodgkin’s Disease (LPHD). Long-Term Results of a Phase-II Study from the German Hodgkin Lymphoma Study Group (GHSG).

Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 1503-1503
Author(s):  
Holger Schulz ◽  
Sven Trelle ◽  
Marcel Reiser ◽  
Marcus Sieber ◽  
Volker Diehl ◽  
...  
Keyword(s):  
T Cell ◽  
B Cell ◽  
Hodgkin Lymphoma ◽  
Phase Ii ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Study Group ◽  
Cd20 Antibody ◽  
Lymphoma Study Group ◽  
Anti Cd20

Abstract Introduction: LPHD is a rare disease which accounts for 3–8% of all Hodgkin cases. Patients with LPHD relapse frequently and freedom from treatment failure is not significantly improved by intensification of polychemotherapy or radiotherapy. The malignant cells of LPHD are CD20+ and therefore the anti-CD20 antibody rituximab (R) may have activity with fewer adverse late effects. Methods: This phase-II trial was initiated by the German Hodgkin Lymphoma Study Group (GHSG) to evaluate rituximab in patients with LPHD at first or higher relapse or progressive disease after at least one standard treatment. Histological slides were reviewed by a reference panel. Pts received 375mg/m2 of the anti-CD20 antibody rituximab once weekly for four weeks given as intravenous infusion in saline solution. Results: Between 1999 and 2004 we treated twenty-one pts. with CD20-positive Hodgkin’s lymphoma according to the study protocol. Fourteen patients had stage I/II disease at the time of study entry and all patients were in their first to third relapse (median 2). The initial diagnosis of LPHD was confirmed in 17/21 cases. The remaining cases were reclassified as HD transformed to T-cell rich B-cell lymphoma (2) or CD20-positive classical HD (2). The overall response rate was 90%. Time to progression was 31 months (ms). The median follow-up 58 ms. Both T-cell rich B-cell lymphoma are in continous remission (PR 51ms+, CR 61ms+). Conclusion: Single-agent therapy with rituximab is safe and showed high efficacy in relapsed LPHD. Therefore rituximab might be a non-toxic and efficient alternative treatment strategy compared to intensified chemo-and/or radiotherapeutic protocols in this young group of patients.

scholarly journals Low serum albumin is an independent risk factor in elderly patients with aggressive B‐cell lymphoma: Results from prospective trials of the German High‐Grade Non‐Hodgkin's Lymphoma Study Group

eJHaem ◽  
2020 ◽  
Vol 1 (1) ◽  
pp. 181-187
Author(s):  
Karin Hohloch ◽  
Marita Ziepert ◽  
Lorenz Truemper ◽  
Christian Buske ◽  
Gerhard Held ◽  
...  
Keyword(s):  
Risk Factor ◽  
Independent Risk Factor ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Study Group ◽  
High Grade ◽  
Prospective Trials ◽  
Lymphoma Study Group ◽  
Aggressive B Cell Lymphoma ◽  
Low Serum

Diffuse Large B-cell Lymphoma Arising in Nodular Lymphocyte Predominant Hodgkin Lymphoma: a Report of 21 Cases from the Nebraska Lymphoma Study Group

2004 ◽  
Vol 45 (8) ◽  
pp. 1551-1557 ◽  
Author(s):  
James Z Huang ◽  
Dennis D Weisenburger ◽  
Julie M Vose ◽  
Timothy C Greiner ◽  
Patricia Aoun ◽  
...  
Keyword(s):  
B Cell ◽  
Hodgkin Lymphoma ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Study Group ◽  
Large B Cell Lymphoma ◽  
Lymphoma Study Group ◽  
Large B Cell

scholarly journals Relevance of ID3-TCF3-CCND3 pathway mutations in pediatric aggressive B-cell lymphoma treated according to the non-Hodgkin Lymphoma Berlin-Frankfurt-Münster protocols

Haematologica ◽  
2017 ◽  
Vol 102 (6) ◽  
pp. 1091-1098 ◽  
Author(s):  
Marius Rohde ◽  
Bettina R. Bonn ◽  
Martin Zimmermann ◽  
Jonas Lange ◽  
Anja Möricke ◽  
...  
Keyword(s):  
B Cell ◽  
Hodgkin Lymphoma ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Non Hodgkin Lymphoma ◽  
Aggressive B Cell Lymphoma

scholarly journals High-dose CHOP plus etoposide (MegaCHOEP) in T-cell lymphoma: a comparative analysis of patients treated within trials of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL)

2009 ◽  
Vol 20 (12) ◽  
pp. 1977-1984 ◽  
Author(s):  
M. Nickelsen ◽  
M. Ziepert ◽  
S. Zeynalova ◽  
B. Glass ◽  
B. Metzner ◽  
...  
Keyword(s):  
Comparative Analysis ◽  
T Cell ◽  
Hodgkin Lymphoma ◽  
Cell Lymphoma ◽  
T Cell Lymphoma ◽  
High Dose ◽  
Study Group ◽  
High Grade ◽  
Non Hodgkin Lymphoma ◽  
Lymphoma Study Group

Metody cytogenetyki molekularnej w różnicowaniu agresywnych B-NHL

2019 ◽  
Vol 50 (3) ◽  
pp. 109-115
Author(s):  
Beata Grygalewicz
Keyword(s):  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
World Health ◽  
High Grade ◽  
Non Hodgkin Lymphoma ◽  
Large B Cell Lymphoma ◽  
Health Organization ◽  
Large B Cell

StreszczenieB-komórkowe agresywne chłoniaki nieziarnicze (B-cell non-Hodgkin lymphoma – B-NHL) to heterogenna grupa nowotworów układu chłonnego, wywodząca się z obwodowych limfocytów B. Aberracje cytogenetyczne towarzyszące B-NHL to najczęściej translokacje onkogenów takich jak MYC, BCL2, BCL6 w okolice genowych loci dla łańcuchów ciężkich lub lekkich immunoglobulin. W niektórych przypadkach dochodzi do wystąpienia kilku wymienionych aberracji jednocześnie, tak jak w przypadkach przebiegających z równoczesną translokacją genów MYC i BCL2 (double hit), niekiedy także z obecnością rearanżacji BCL6 (triple hit). Takie chłoniaki cechuje szczególnie agresywny przebieg kliniczny. Obecnie molekularna diagnostyka cytogenetyczna przy użyciu techniki fluorescencyjnej hybrydyzacji in situ (FISH) oraz, w niektórych przypadkach, aCGH jest niezbędnym narzędziem rozpoznawania, klasyfikowania i oceny stopnia zaawansowania agresywnych, nieziarniczych chłoniaków B-komórkowych. Technika mikromacierzy CGH (aCGH) była kluczowym elementem wyróżnienia prowizorycznej grupy chłoniaków Burkitt-like z aberracją chromosomu 11q (Burkitt-like lymphoma with 11q aberration – BLL, 11q) w najnowszej klasyfikacji nowotworów układu chłonnego Światowej Organizacji Zdrowia (World Health Organization – WHO) z 2016 r. Omówione zostaną sposoby różnicowania na poziomie cytogenetycznym takich chłoniaków jak: chłoniak Burkitta (Burkitt lymphoma – BL), chłoniak rozlany z dużych komórek B (diffuse large B-cell lymphoma – DLBCL) oraz 2 nowych jednostek klasyfikacji WHO 2016, czyli chłoniaka z komórek B wysokiego stopnia złośliwości z obecnością translokacji MYC i BCL2 i/lub BCL6 (high-grade B-cell lymphoma HGBL, with MYC and BCL2 and/or BCL6 translocations) oraz chłoniaka BLL, 11q.

Sign in / Sign up

Export Citation Format

Share Document